NPC
IPXL

National Planning Corporation’s Impax Laboratories, Inc. IPXL Stock Holding History

National Planning Corporation’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-900
Closed -$27.9K – 2427
2014
Q4 		$27.9K Buy
+900
New +$26.3K ﹤0.01% 1556

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

National Planning Corporation's IPXL Position: Q1 2015 in Review

National Planning Corporation sold out of Impax Laboratories, Inc. (IPXL) in Q1 2015, closing a stake of 900 shares — an estimated $27.9K sold.

National Planning Corporation first reported a position in IPXL in Q4 2014 and held it in 1 quarter. The position peaked at $27.9K in Q4 2014. 197 funds tracked by Wall St. Rank hold IPXL as of Q1 2015.

  • National Planning Corporation reported no remaining Impax Laboratories, Inc. position as of Q1 2015 after selling out during the quarter.
  • National Planning Corporation sold 900 Impax Laboratories, Inc. shares in Q1 2015, an estimated $27.9K.
  • National Planning Corporation first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 1 quarter.
  • National Planning Corporation's Impax Laboratories, Inc. position peaked at $27.9K in Q4 2014.
  • 197 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2015.

Based on National Planning Corporation's 13F filing for Q1 2015, filed 12 May 2015.